Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
A Single Center, Prospective, Blinded Study to Evaluate the Efficacy and Safety of a Tripeptide/Hexapeptide Topical When Used With Er:YAG Hybrid Laser for the Treatment of Acne Scars
Sponsor: University of Rochester
This NA trial investigates Acne Scars - Mixed Atrophic and Hypertrophic and is currently completed. University of Rochester leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
May 2023 — Jul 2024 [monthly]
Completed NA
-
Sep 2021 — May 2023 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
▶ Show 3 earlier versions
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .